A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants With Moderate to Severe AD

Activo, no reclutaFase 2ClinicalTrials.gov

ID: NCT06881251Tipo: INTERVENTIONALInicio: 26 de feb de 2025Fin estimado: 26 de mar de 2026

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Chronic Atopic Dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset of symptoms at least 1 year prior to the screening visit
Eczema Area and Severity Index (EASI) score greater than and equal to (\>=) 16 at the screening and baseline visits
Validated investigator global assessment for AD (vIGA-AD) score \>= 3 at the screening and baseline visits
\>= 10% body surface area (BSA) of AD involvement at the screening and baseline visits
Baseline Peak Pruritus Numeric(al) Rating Scale (PP-NRS) average score of \>=4
Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, or inadequate response to systemic therapies (within 12 months before screening)
Participant has applied a moisturizer at least once daily for at least 7 days before the baseline visit

Criterios de exclusión

Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents (eg, severe ocular surface disease, dupilumab-associated facial redness) inhibiting IL-4Rα, IL-4, and/or IL-13 signaling (eg, dupilumab, lebrikizumab, or tralokinumab)
Participant is pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study
Active skin disease other than AD including eczema herpeticum, molluscum contagiosum, impetigo, psoriasis or has any other ongoing significant skin condition including skin infections, that, according to the investigator, could interfere with efficacy assessments
Current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Recent case of eczema herpeticum, herpes zoster within 8 weeks before screening, or history of recurrent eczema herpeticum
History of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (eg, untreated latent tuberculosis), recurrent urinary tract infection, fungal infection, mycobacterial infection, or open, draining, or infected skin wounds, or ulcers.
Diagnosed active parasitic infection or at high risk of parasitic infection, unless treated with antihelminth therapy prior to randomization
Had major surgery (eg, requiring general anesthesia and hospitalization), within 8 weeks before screening, or will not have fully recovered from surgery, or has such surgery planned during the time the participant is expected to participate in the study

Intervenciones

drug

Dupilumab

Dupilumab will be administered subcutaneously.

drug

JNJ-95475939

JNJ-95475939 will be administered subcutaneously.

drug

Placebo

Placebo will be administered subcutaneously.

Ubicaciones

CIPREC

Buenos Aires, Argentina

INAER - Investigación en Alergias y Enfermedades Respiratorias

Buenos Aires, Argentina

Instituto de Neumonologia y Dermatologia

Buenos Aires, Argentina

Derma Internacional S A

Buenos Aires, Argentina

Patrocinadores

PrincipalJanssen Research & Development, LLC

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 2b, Multicenter, Randomized, Double-blind, Placeb... | EligiMed